William Blair initiated coverage on Lifecore Biomedical
$LFCR
Biotechnology: Pharmaceutical Preparations
Health Care
William Blair initiated coverage of Lifecore Biomedical with a rating of Outperform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/4/2025 | Sector Weight | KeyBanc Capital Markets | |
| 5/21/2025 | Outperform | William Blair | |
| 9/5/2024 | $8.00 | Buy | Craig Hallum |
| 8/28/2024 | Outperform → Mkt Perform | Barrington Research | |
| 3/20/2023 | $11.00 → $2.00 | Overweight → Equal-Weight | Stephens |
4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
-- Recorded $31.1 Million in Revenue During the Three Months Ended September 30, 2025, Representing a 26% Increase From Comparable Period of 2024 -- -- Multiple New Programs Signed with New Customers -- -- Continued Improvements in Efficiency and Productivity Across the Organization -- Conference Call Today at 4:30pm ET CHASKA, Minn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced its financial results for the three months ended September 30, 2025. Highlights for Three Months Ended September 30, 2025 "We are thrilled with the progress made during t
CHASKA, Minn., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it will report financial results for the three months ended September 30, 2025, on Thursday, November 6, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore's senior management team will host a webcast to discuss the results. To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore's website at: https://ir.lifecore.com/events-presentations. Following the live webcast, an archived version
Lifecore to Execute Commercial Site Transfer and Become New Supplier of Choice for Leading Commercial Injectable Pharmaceutical Product Represents Second Agreement Signed with Same Major Multinational Organization in Recent Months Separate Pre-Clinical Formulation Development Agreement Signed with New Early-Stage Biotech Customer CHASKA, Minn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has signed an agreement with a leading global pharmaceutical company. Under the terms of the agreement, Lifecore will transfer the commercial manufacturin
4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
KeyBanc Capital Markets initiated coverage of Lifecore Biomedical with a rating of Sector Weight
William Blair initiated coverage of Lifecore Biomedical with a rating of Outperform
Craig Hallum initiated coverage of Lifecore Biomedical with a rating of Buy and set a new price target of $8.00
10-Q - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
Mr. DaFonseca Possesses Nearly 30 Years of Broad Drug Development Experience, including More than 15 Years Leading High Performing CDMO Sales Organizations Will Leverage Deep Pharma Services Expertise as Leader of Lifecore's Sales Organization Focused on Executing Three-Pronged Growth Strategy CHASKA, Minn., May 27, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has appointed Mark DaFonseca as chief commercial officer. A seasoned CDMO and pharmaceutical services executive, Mr. DaFonseca has nearly 30 years of pharmaceutical industry experience spannin
Mr. Salus Brings More than 30 Years of Broad-Based Legal and Management Expertise Highlighted by Extensive Experience within Life Sciences Industry Significantly Elevates Lifecore's Capabilities Across Corporate Governance, Transactional Activities, and SEC Reporting and Compliance CHASKA, Minn., April 14, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has appointed Thomas (Tom) Salus as chief legal and administration officer and corporate secretary. A business-focused, hands-on executive, Mr. Salus has more than 30 years of broad-based legal and manage
Brings Strong Background in Pharmaceutical Manufacturing Operations and Finance to Help Drive Performance and Productivity Jackie Klecker Named Executive Vice President, Quality and Development Services to Focus on Sustaining Company's Strong Regulatory and Compliance Track Record Personnel Moves Bifurcate Operations and Quality Functions to Align with Company's Growth Strategy and Reflect Natural Evolution of Business CHASKA, Minn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has appointed Thomas Guldager as vice president, operations. An
-- Recorded $31.1 Million in Revenue During the Three Months Ended September 30, 2025, Representing a 26% Increase From Comparable Period of 2024 -- -- Multiple New Programs Signed with New Customers -- -- Continued Improvements in Efficiency and Productivity Across the Organization -- Conference Call Today at 4:30pm ET CHASKA, Minn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced its financial results for the three months ended September 30, 2025. Highlights for Three Months Ended September 30, 2025 "We are thrilled with the progress made during t
CHASKA, Minn., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it will report financial results for the three months ended September 30, 2025, on Thursday, November 6, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore's senior management team will host a webcast to discuss the results. To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore's website at: https://ir.lifecore.com/events-presentations. Following the live webcast, an archived version
-- Recorded $128.9 Million in Fiscal 2025 Revenue, Meeting Full-Year Guidance; Maintains Commitment to Mid-Term Outlook -- -- Nine New Programs Signed with New Customers During Fiscal 2025, Reflecting Growth into Modalities Beyond the Company's Traditional Area of Strength in Ophthalmic Therapeutics -- -- Improved Efficiency and Productivity Across the Organization -- Conference Call Today at 4:30pm ET CHASKA, Minn., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced its financial results for the fourth quarter and fiscal year 2025. Fourth Quarter and
SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)
SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)
SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)